0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Effects of Empagliflozin on Cardiorespiratory Fitness and Significant Interaction of Loop Diuretics

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          The effects of empagliflozin on cardiorespiratory fitness in patients with type 2 diabetes mellitus (T2DM) and heart failure with reduced ejection fraction (HFrEF) are unknown.

          Methods

          In this pilot study we determined the effects of empagliflozin10 mg/day for four weeks on peak oxygen consumption (VO 2) in 15 patients with T2DM and HFrEF. As exploratory analysis, we assessed whether there was an interaction for the effects of empagliflozin on peak VO 2 of loop diuretics.

          Results

          Empagliflozin reduced body weight (−1.7 Kg, p=0.031), but it did not change peak VO 2 (from 14.5 mL•kg −1•min −1 [12.6–17.8] to 15.8 [12.5–17.4] mL•kg −1•min −1, p=0.95). However, patients on loop diuretics (N=9) demonstrated an improvement, whereas those without loop diuretics (N=6) had a decrease in peak VO 2 (+0.9[0.1–1.4] vs −0.9[−2.1– −0.3] mL•kg −1•min −1, p=0.001), and peak VO 2 changes correlated with the baseline daily dose of diuretics (R=+0.83, p<0.001).

          Conclusions

          Empagliflozin did not improve peak VO 2 in patients with T2DM and HFrEF. However, as result of exploratory analysis, patients concomitantly treated with loop diuretics experienced a significant improvement in peak VO 2.

          Related collections

          Author and article information

          Journal
          100883645
          22008
          Diabetes Obes Metab
          Diabetes Obes Metab
          Diabetes, obesity & metabolism
          1462-8902
          1463-1326
          31 March 2018
          23 April 2018
          August 2018
          01 August 2019
          : 20
          : 8
          : 2014-2018
          Affiliations
          [1 ]VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA
          [2 ]Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
          [3 ]Kinesiology and Health Science, Virginia Commonwealth University Richmond, VA, USA
          [4 ]Department of Pharmacotherapy and Outcome Sciences, Virginia Commonwealth University, Richmond, VA, USA
          [5 ]Division of Cardiovascular Medicine and Department of Pharmacy Service, Brigham and Women’s Hospital, Boston, MA, USA
          Author notes
          Address for correspondence: Salvatore Carbone, PhD, Research Instructor of Medicine, VCU Pauley Heart Center, Virginia Commonwealth University, West Hospital, 5 th Floor, Room 520, 1200 E Broad Street, P.O. Box 980204, Richmond, VA, 23298, Tel: (804) 628-3980 - Fax: (804) 628-3984, salvatore.carbone@ 123456vcuhealth.org
          Article
          PMC6043379 PMC6043379 6043379 nihpa956018
          10.1111/dom.13309
          6043379
          29603546
          Categories
          Article

          Comments

          Comment on this article